Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for […]
Read MoreLRAD Corporation designs, develops, and commercializes directed sound technologies and products in North and South America, Europe, the Middle East, Africa, and Asia. It develops directed acoustic communication systems that focus sound over short and long distances. The company offers directional and omnidirectional acoustic systems and accessories. It offers Long Range Acoustic Device primarily for […]
Read MoreDHT Holdings, Inc., through its subsidiaries, owns and operates crude oil tankers primarily in Oslo, Norway and Singapore. As of February 6, 2018, it had a fleet of 27 very large crude carriers and 2 Aframaxes with deadweight tons of 8,590,740. The company was founded in 2005 and is headquartered in Hamilton, Bermuda. Annual EPS […]
Read MoreChinese stocks are starting to show life again, and these 2 stocks are looking ripe of the picking.
Read MoreThe Consumer Discretionary sector cuts a wide swath across the economic landscape of the United States. It’s easy to think about the sector as the place you’ll find retail stocks, but the truth is that there are a lot of other businesses within the sector that are much more than just the department stores and […]
Read MoreHe’s up 25% so far this year thanks to some key new stakes and outperformance with prior investments.
Read MoreHere are the 15 stocks they say investors should consider. The S&P 500 is up nearly 17% since its low hit on Christmas Eve when the index briefly dropped into bear market territory, but Goldman Sachs (NYSE: GS) is warning that this rally is about to stall. This surge since December 24 marks the fastest […]
Read MoreIt also could be a bad omen. Here’s why.
Read MoreMid-Con Energy Partners, LP engages in the ownership, acquisition, and development of producing oil and natural gas properties in North America. The company’s properties are primarily located in the Mid-Continent and Permian Basin regions of the United States in Oklahoma and Texas. As of December 31, 2017, its total estimated proved reserves of approximately 19.6 […]
Read MoreAnd it has nothing to to with China or the Fed…
Read MoreI know – it’s cheesy to use Valentine’s Day as a tagline today. And it’s also more than a little odd to use it with a tech stock. Even so, NVIDIA Corporation (NVDA) is set to make its latest quarterly earnings report after the market closes today, and the fact is that this is a […]
Read MoreWith trade tiffs, earnings reports, and politics largely dominating the more visible areas of the stock market, it’s important for investors to divert their attention to the smaller, often overlooked companies every once in a while. When it comes to overlooked companies, no type of equity falls more into that category than penny stocks. So […]
Read MoreMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making […]
Read MoreWhen it comes to identifying stocks that might make useful investments, there are as many strategies as there are people. You can break these strategies into any different number of categories. I like to differentiate between strategies by thinking first about the amount of time I might actually plan to hold the stock in question, […]
Read MorevTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company’s drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer’s disease. Annual EPS Growth – Companies […]
Read More